REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDeltex Medical Regulatory News (DEMG)

Share Price Information for Deltex Medical (DEMG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.12
Bid: 0.11
Ask: 0.13
Change: 0.00 (0.00%)
Spread: 0.02 (18.182%)
Open: 0.12
High: 0.12
Low: 0.12
Prev. Close: 0.12
DEMG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors' Share Dealings

30 Mar 2009 16:46

RNS Number : 7448P
Deltex Medical Group PLC
30 March 2009
 



Deltex Medical Group plc

Directors' share dealings

30 March 2009 Deltex Medical Group plc ("Deltex Medical" or the "Company")the global leader in oesophageal Doppler monitoring ("ODM")announces that Julian Cazalet a non-executive Director, has today notified the Company that on 26 March 2009 he purchased 500,000 ordinary shares of 1p each in the Company ("Shares") at 8 pence per share. 

Following the above purchase, Julian Cazalet owns 1,750,000 ordinary shares representing 1.74 per cent. of the Company's issued share capital. 

The Company also received notification today from New England Partners Capital, that it had disposed of 2,285,714 Shares at pence per Share on 26 March 2009 and no longer has a notifiable interest. Edwin Snape, a non-executive Director both personally and through his role as a principal of Nexus Medical Partners, a Deltex Medical shareholder, now has an interest in 4,478,896 Shares, representing 4.46 per cent. of the Company's issued share capital. Edwin Snape is also a principal of New England Partners Capital, a venture capital fund which is in the process of being wound up.

For further information, please contact:- 

 

Deltex Medical Group plc 01243 774 837

Nigel Keen, Chairman   njk@deltexmedical.com

Andy Hill, Chief Executive ahill@deltexmedical.com  

Ewan Phillips, Finance Director  eap@deltexmedical.com

 

Nominated Adviser & Broker

Arden Partners plc 020 7398 1630

Chris Hardie chris.hardie@arden-partners.com

Matthew Armitt matthew.armitt@arden-partners.com  

Notes for Editors 

Deltex Medical manufactures and markets the CardioQ-ODM(TM) monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. 

Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier. 

 

The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay. 

 

There are already over 1,600 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. Over 1,000 patients a week are treated using the CardioQ-ODM. In addition, there are currently approximately 200 clinical publications on the use of the CardioQ-ODM which have repeatedly:- 

 

Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works 

Proved that the CardioQ-ODM works in a wide range of surgical procedures 

Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. 

The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSSDLFISSUSELD
Date   Source Headline
8th May 202412:50 pmRNSResult of Annual General Meeting
8th May 20247:00 amRNSChairman’s Statement to the Annual General Meeting
8th Apr 20245:03 pmRNSHolding(s) in Company
8th Apr 20247:00 amRNSPosting of Annual Report & Notice of AGM
28th Mar 20247:00 amRNSResults for the year ended 31 December 2023
2nd Feb 20245:11 pmRNSHolding(s) in Company
31st Jan 20245:00 pmRNSTotal Voting Rights
18th Jan 20245:01 pmRNSIssue of Equity
18th Jan 20247:00 amRNSYear-end trading update
4th Dec 20237:00 amRNSCommercial update, board changes & new auditor
18th Sep 20237:00 amRNSInterim results to 30 June 2023
31st Aug 20235:00 pmRNSTotal Voting Rights
2nd Aug 20236:23 pmRNSHolding(s) in Company
2nd Aug 20235:32 pmRNSHolding(s) in Company
2nd Aug 20238:00 amRNSFundraising completion, trading restoration & TVR
2nd Aug 20237:30 amRNSRestoration - Deltex Medical Group PLC
1st Aug 202310:04 amRNSResult of General Meeting
24th Jul 20237:00 amRNSResult of Retail Offer
18th Jul 20234:47 pmRNSExtension of Retail Offer Closing Time
14th Jul 20236:03 pmRNSRetail offer to raise up to £500,000
14th Jul 20236:01 pmRNSPlacing, Subscription and Retail Offer
10th Jul 20237:00 amRNSRelease of new next generation TrueVue System
6th Jul 20237:13 amRNSHalf-year Trading Update & Potential Fundraise
26th Jun 20237:30 amRNSSuspension - Deltex Medical Group PLC
26th Jun 20237:00 amRNSTrading update and suspension of trading on AIM
19th May 20231:35 pmRNSHolding(s) in Company
17th May 20233:24 pmRNSResult of AGM
17th May 20237:00 amRNSChairman’s Statement to the Annual General Meeting
28th Apr 20235:00 pmRNSTotal Voting Rights
25th Apr 20237:00 amRNSNew monitor launch update & new loan facility
11th Apr 20235:43 pmRNSIssue of Equity
30th Mar 20237:00 amRNSResults for the year ended 31 December 2022
27th Feb 20237:00 amRNSConvertible loan notes repayment date extension
24th Jan 20237:00 amRNSYear end trading update
22nd Dec 20227:00 amRNSYear end update
20th Sep 20227:00 amRNSInterim Results
14th Jul 20227:00 amRNSCompletion of Nominated Adviser due diligence
7th Jul 20227:00 amRNSHalf year trading update
18th May 20223:41 pmRNSResult of AGM
18th May 20227:00 amRNSChairman's Statement to Annual General Meeting
28th Apr 20227:00 amRNSChange of Adviser
7th Apr 20227:00 amRNSResults for the year ended 31 December 2021
2nd Mar 20224:30 pmRNSHolding(s) in Company
17th Feb 20224:02 pmRNSGrant of options
8th Feb 20227:00 amRNSSubscription and extension of Debt Facility
26th Jan 20227:00 amRNSContract win in the Americas
12th Jan 20227:00 amRNSIssue of Equity
11th Jan 20227:00 amRNSPre-close statement
20th Dec 20217:00 amRNSSuccessful Innovate UK Smart Award
20th Sep 20217:00 amRNSInterim results to 30 June 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.